AlanP.Zausner SkarbnikMD

PubMed

• 96 citations
  Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatme...
  Jeff P Sharman, Miklos Egyed, Wojciech Jurczak, Alan Skarbnik, John M Pagel
  Leukemia. 2022-04-01
• 53 citations
  Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.
  Anthony R. Mato, Lindsey E. Roeker, John N. Allan, John M. Pagel, Danielle M. Brander
  American Journal of Hematology. 2018-11-01
• 7 citations
  Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.
  Franck Morschhauser, Saurabh Dahiya, M Lia Palomba, Alejandro Martin Garcia-Sancho, Juan Luis Reguera Ortega
  Nature Medicine. 2024-08-01

Abstracts/Posters

• Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
  Alan Skarbnik, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents
  Alan Skarbnik, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• An Innovative Telemedicine Platform to Provide Expert Access to Patients with Chronic Lymphocytic Leukemia (CLL)
  Alan Skarbnik, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients
  Alan Skarbnik, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocy...
  Alan Skarbnik, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study
  Alan Skarbnik, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
  Alan Skarbnik, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Phase I/II Study of Escalating Doses of Thalidomide in Conjunction with Bortezomib and High Dose Melphalan As a Conditioning Regimen for Autologous Stem Cell Transplan... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Elevated IL-1Ra Levels in the Stem Cell Product Is Associated with the Development of Engraftment Syndrome Following Autologous Stem Cell Transplantation for the Treat... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018